Tularemia

Tularemia is a zoonotic bacterial disease caused by the facultative intracellular gram-negative coccobacillus Francisella tularensis. It affects a wide range of mammalian species, including domestic cats and dogs, as well as humans. The disease is characterized by acute febrile illness, lymphadenopathy, septicemia, and potentially fatal systemic involvement. In veterinary medicine, tularemia is primarily recognized in cats, which are highly susceptible and can serve as sentinels for human exposure. The disease manifests in several clinical forms, including ulceroglandular, glandular, oculoglandular, oropharyngeal, pneumonic, and typhoidal (septicemic) forms, depending on the route of inoculation and host immune status. In domestic animals, the most common presentations are the ulceroglandular form (following cutaneous inoculation) and the typhoidal form (following ingestion or inhalation). The disease is a significant public health concern due to its high infectivity and potential for bioterrorism, classified as a Category A agent by the CDC.

The primary causative agent is Francisella tularensis, a small, pleomorphic, facultative intracellular, non-motile, non-spore-forming, aerobic gram-negative coccobacillus. It is classified into four subspecies: F. tularensis subsp. tularensis (Type A), F. tularensis subsp. holarctica (Type B), F. tularensis subsp. mediasiatica, and F. tularensis subsp. novicida. Type A is the most virulent and is found predominantly in North America, associated with lagomorphs (rabbits and hares) and ticks. Type B is less virulent and distributed across the Northern Hemisphere, associated with aquatic rodents (beavers, muskrats) and arthropods. The bacterium possesses a unique lipopolysaccharide that is poorly immunogenic, allowing it to evade the host immune response. It survives within macrophages by escaping the phagosome into the cytosol, where it replicates. Virulence factors include a capsule-like structure, type IV pili, and the Francisella pathogenicity island (FPI) encoding a type VI secretion system essential for intracellular survival. Transmission occurs via tick bites (e.g., Dermacentor, Amblyomma, Ixodes species), deer fly bites, contact with infected tissues or fluids (especially during skinning of rabbits), ingestion of contaminated water or meat, and inhalation of aerosolized bacteria. In cats, hunting and ingestion of infected prey (rabbits, rodents) are common routes. The bacterium is highly infectious; as few as 10 organisms can cause disease in humans.

Tularemia is a zoonotic disease with a wide geographic distribution, primarily in the Northern Hemisphere, including North America, Europe, and Asia. In the United States, most cases occur in the south-central and western states (Arkansas, Missouri, Oklahoma, South Dakota). The disease is more common in rural areas and during warmer months (May to September), correlating with tick and deer fly activity. Domestic cats are the most commonly affected companion animals, with a higher incidence in outdoor cats that hunt. Dogs are less susceptible but can become infected through ingestion or tick bites. There is no breed or age predilection, but young, active hunting cats are at increased risk. In endemic areas, seroprevalence in cats can be significant, indicating subclinical exposure. Human cases often occur in clusters, and veterinarians and veterinary technicians are at occupational risk due to potential exposure to infected animals. The disease is not transmitted directly from person to person. In animals, outbreaks are sporadic, but epizootics can occur in rabbit populations, increasing the risk of transmission to domestic animals.

After inoculation (via skin, mucous membranes, inhalation, or ingestion), Francisella tularensis invades host cells, primarily macrophages and dendritic cells. The bacterium adheres to cell surface receptors (e.g., complement receptors) and is phagocytosed. It then escapes the phagosome into the cytosol, where it replicates, ultimately causing cell lysis and release of bacteria. This triggers a robust innate immune response, with activation of NLRP3 inflammasome and production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). The bacteria disseminate via the lymphatic system to regional lymph nodes, causing lymphadenopathy, and then to the bloodstream, leading to bacteremia and systemic spread to the liver, spleen, lungs, and bone marrow. The typhoidal form results from overwhelming bacteremia and septic shock. The bacterium's ability to suppress host immune responses, particularly by inhibiting T-cell responses and promoting a Th2-type response, contributes to its virulence. Pathological findings include focal necrosis and granulomatous inflammation in affected organs, particularly the liver and spleen. In the lungs, bronchopneumonia and pleural effusion may occur. Disseminated intravascular coagulation (DIC) and multi-organ failure can ensue in severe cases.

Intrinsic factors include species susceptibility: cats are highly susceptible, while dogs are relatively resistant. Age and immune status play a role; immunocompromised animals (e.g., FIV/FeLV-infected cats) are at higher risk for severe disease. Extrinsic factors include outdoor access, hunting behavior, and exposure to tick-infested environments. Ingestion of raw meat from infected prey (rabbits, rodents) is a major risk factor. Lack of ectoparasite control increases the risk of tick-borne transmission. Occupational exposure in veterinary settings, such as handling infected animals without appropriate personal protective equipment, is a risk for humans but not for animals. Seasonal and geographic factors (endemic areas) also predispose to infection.

Clinical signs in cats and dogs typically appear 2-5 days after exposure. The peracute form may present with sudden death, especially in kittens. Acute signs include high fever (104-106°F), lethargy, depression, anorexia, and dehydration. Lymphadenopathy is common, with enlarged, painful lymph nodes (cervical, submandibular, prescapular, popliteal). Ulceroglandular form: a cutaneous ulcer at the inoculation site (e.g., paw, face) with regional lymphadenopathy. Oropharyngeal form: oral ulcers, tonsillitis, pharyngitis, and cervical lymphadenopathy, often after ingestion. Oculoglandular form: conjunctivitis, ocular discharge, and periauricular lymphadenopathy. Pneumonic form: cough, dyspnea, tachypnea, and nasal discharge. Typhoidal form: severe systemic signs including high fever, vomiting, diarrhea, abdominal pain, hepatosplenomegaly, and signs of septic shock (pale mucous membranes, prolonged capillary refill time, tachycardia, weak pulses). Chronic cases may present with weight loss, persistent fever, and recurrent abscesses. In dogs, signs are often milder, with fever, lethargy, and localized lymphadenopathy.

Differential diagnoses include: 1) Plague (Yersinia pestis): acute fever, lymphadenopathy (buboes), and septicemia; differentiate by Gram stain (bipolar 'safety pin' appearance), culture on selective media, and PCR; both are zoonotic and require similar biosafety precautions. 2) Cat-scratch disease (Bartonella henselae): lymphadenopathy and fever, but typically a history of a cat scratch; diagnosis via serology, PCR, or Warthin-Starry silver stain. 3) Abscesses due to pyogenic bacteria (e.g., Staphylococcus, Streptococcus): localized swelling, pain, and purulent discharge; respond to routine antibiotics; culture and cytology. 4) Lymphoma: generalized lymphadenopathy, but often in older animals, with cytology/histopathology showing neoplastic lymphocytes. 5) Mycobacterial infections: chronic granulomatous lesions, lymphadenopathy, and weight loss; acid-fast staining and culture. 6) Fungal infections (e.g., histoplasmosis, blastomycosis): respiratory signs, lymphadenopathy, and disseminated disease; cytology/histopathology with fungal organisms. 7) Tick-borne diseases (e.g., ehrlichiosis, anaplasmosis): fever, thrombocytopenia, and lymphadenopathy; serology/PCR. 8) Toxoplasmosis: fever, lymphadenopathy, and systemic signs; serology and PCR. 9) Septicemia from other gram-negative bacteria: similar systemic signs; blood cultures.

1) Clinical suspicion: acute febrile illness with lymphadenopathy in an outdoor cat with a history of hunting or tick exposure. 2) Initial diagnostic tests: CBC, serum biochemistry, urinalysis, and blood smear for cytology. 3) Serology: acute and convalescent (2-4 weeks apart) titers for F. tularensis antibodies; a 4-fold rise is diagnostic. 4) PCR: on whole blood, lymph node aspirates, or tissue samples; highly sensitive and specific. 5) Culture: on cysteine-enriched media (e.g., chocolate agar with cysteine); requires biosafety level 3 precautions; notify laboratory of suspicion. 6) Imaging: thoracic radiographs if respiratory signs; abdominal ultrasound if hepatosplenomegaly. 7) Cytology/histopathology: lymph node aspirate or biopsy showing necrotizing granulomatous inflammation; special stains (Gram, Giemsa, immunofluorescence) may reveal organisms. 8) Rule out differentials: testing for plague, bartonellosis, and other tick-borne diseases. 9) Public health notification: report suspected cases to public health authorities.

Hematology: leukopenia or leukocytosis with left shift, thrombocytopenia, and anemia (in chronic cases). Serum biochemistry: elevated liver enzymes (ALT, AST), hyperbilirubinemia, azotemia (renal involvement), hypoalbuminemia, and electrolyte imbalances (hyponatremia, hypokalemia). Urinalysis: proteinuria, hematuria, and casts in renal involvement. Blood gas analysis: metabolic acidosis in septic shock. Specific biomarkers: increased C-reactive protein (CRP), procalcitonin (if available), and possibly elevated troponin I in myocarditis. Serology: ELISA or microagglutination tests for antibodies; IgM appears early, IgG later. PCR: positive for F. tularensis DNA in blood, lymph node aspirates, or tissues. Culture: growth on cysteine-supplemented media; confirmatory biochemical tests (catalase positive, oxidase negative).

Radiography: thoracic radiographs may show interstitial or alveolar patterns, bronchopneumonia, and pleural effusion in the pneumonic form. Abdominal radiographs may reveal hepatosplenomegaly. Ultrasonography: abdominal ultrasound can show hepatosplenomegaly, lymphadenopathy, and focal hypoechoic lesions (abscesses or granulomas) in the liver and spleen. Echocardiography: not typically indicated, but may show pericardial effusion in rare cases. CT/MRI: advanced imaging may be used to evaluate deep lymph nodes or organ abscesses, but is rarely necessary. Endoscopy: not routinely used, but may be helpful in oropharyngeal form to visualize pharyngeal ulcers.

Cytology of lymph node aspirates: may show pyogranulomatous inflammation with necrotic debris; organisms may be seen with Gram or Giemsa stain as small, pleomorphic coccobacilli. Histopathology of lymph nodes, liver, spleen, or lung: multifocal necrosis with neutrophilic and histiocytic infiltration, granulomatous inflammation, and abscess formation. Special stains: Gram stain (weakly gram-negative), Giemsa, and immunofluorescence can highlight organisms. In chronic cases, fibrosis and caseous necrosis may be present.

Treatment should be initiated promptly based on clinical suspicion, even before confirmatory tests. The drug of choice is an aminoglycoside, such as gentamicin or streptomycin. Gentamicin: 5-8 mg/kg IV, IM, or SC once daily (or divided q8h) for 7-10 days. Streptomycin: 10-15 mg/kg IM q12h for 7-10 days. Alternative: doxycycline (5-10 mg/kg PO q12h) or a fluoroquinolone (e.g., enrofloxacin 5-10 mg/kg PO or IM q24h) for 14 days, but these are less effective in severe cases. Supportive care: intravenous fluid therapy with crystalloids (e.g., lactated Ringer's solution) at shock rates (e.g., 20-30 ml/kg bolus, then 60-80 ml/kg/day) to maintain perfusion; antiemetics (e.g., maropitant 1 mg/kg SC q24h) if vomiting; nutritional support (esophagostomy tube if anorexic); and analgesia (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h). In cases of septic shock, vasopressors (e.g., norepinephrine CRI) may be required. Surgical drainage of abscesses may be indicated. Strict isolation of the animal and use of personal protective equipment (gloves, mask, eye protection) by handlers is essential.

Prognosis is guarded to good with early and appropriate antibiotic therapy. The typhoidal form carries a poor prognosis, with mortality rates up to 30-60% in cats despite treatment. Negative prognostic indicators include severe leukopenia, thrombocytopenia, marked azotemia, and respiratory distress. With prompt treatment, most animals recover within 1-2 weeks. Chronic infection or relapse can occur if treatment is inadequate. The zoonotic risk is significant; owners and veterinary staff should be informed and monitored.

Recheck examinations at 7, 14, and 30 days after initiation of treatment. Monitor clinical signs (fever, appetite, lymph node size) and repeat CBC and biochemistry at each visit. Serial serology (paired titers) to confirm diagnosis and monitor response. If using aminoglycosides, monitor renal function (creatinine, BUN, urinalysis) every 2-3 days during treatment. Repeat imaging if pneumonia or organ abscesses were present. Long-term follow-up for 3-6 months to ensure complete resolution. Advise owners on tick control and preventing hunting behavior to reduce re-exposure.

Pearls: 1) Always consider tularemia in a febrile outdoor cat with lymphadenopathy, especially if there is a history of hunting. 2) Use appropriate biosafety precautions when handling suspected cases; wear gloves and a mask. 3) Start treatment with gentamicin immediately if clinical suspicion is high, as delay can be fatal. 4) Notify public health authorities of suspected cases. Pitfalls: 1) Misdiagnosing as a common abscess and prescribing beta-lactam antibiotics (e.g., amoxicillin) which are ineffective. 2) Failure to use a laboratory with biosafety level 3 capabilities for culture, leading to laboratory-acquired infections. 3) Overlooking the zoonotic risk and not informing owners. 4) Discontinuing antibiotics too early, leading to relapse.

Based on Plumb's Veterinary Drug Handbook: 1) Gentamicin: 5-8 mg/kg IV, IM, SC once daily (or divided q8h) for 7-10 days; monitor renal function; avoid in patients with renal disease. 2) Streptomycin: 10-15 mg/kg IM q12h for 7-10 days; less commonly used due to availability. 3) Doxycycline: 5-10 mg/kg PO q12h for 14 days; alternative for mild cases or after initial aminoglycoside therapy. 4) Enrofloxacin: 5-10 mg/kg PO or IM q24h for 14 days; may be used as an alternative, but avoid in young animals due to cartilage effects. 5) Supportive drugs: Maropitant (1 mg/kg SC q24h) for vomiting; Buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) for pain; Famotidine (0.5-1 mg/kg IV/PO q12h) for gastric protection. 6) Fluid therapy: Lactated Ringer's solution or Normosol-R at 60-80 ml/kg/day for maintenance, with boluses for shock. 7) In septic shock: Norepinephrine CRI at 0.05-0.5 mcg/kg/min, titrated to effect. 8) Antidote for aminoglycoside toxicity: none specific; discontinue if renal function deteriorates.

Tularemia is a well-documented zoonosis, but veterinary-specific literature is limited. Key studies include: 1) A retrospective study of feline tularemia cases in the United States (e.g., Baldwin et al., 1991) reported clinical signs and treatment outcomes, showing high mortality in untreated cats. 2) Experimental studies in cats (e.g., by the CDC) demonstrated that gentamicin is effective in clearing bacteremia. 3) Consensus guidelines from the American Veterinary Medical Association (AVMA) and the National Association of State Public Health Veterinarians (NASPHV) recommend prompt diagnosis and treatment, and emphasize the zoonotic risk. 4) A review by Petersen et al. (2009) in Emerging Infectious Diseases highlighted the importance of tularemia as a re-emerging disease and the need for veterinary awareness. 5) The World Health Organization (WHO) guidelines on tularemia provide recommendations for treatment in humans, which are often extrapolated to animals. 6) Recent studies on F. tularensis pathogenesis have identified potential vaccine targets, but no veterinary vaccine is currently available. Overall, evidence supports the use of aminoglycosides as first-line therapy, with doxycycline or fluoroquinolones as alternatives for mild cases.